Neoantigen vaccine spurs immune response in glioblastoma
Glioblastoma is termed an immunologically ‘cold’ tumor – a disadvantage for treatment with immunotherapy – because the brain tumor contains very few immune cells that are required to generate an immune response against the tumor.
In a report, scientists at Dana-Farber Cancer Institute say they have shown that a personalized ‘neoantigen’ vaccine can spur a response against glioblastoma, with immune T-cells generated by the vaccine migrating into the brain tumor, creating a ‘hotter,’ inflamed environment around the cancer cells. The neoantigen vaccine approach has been pioneered in the laboratory of Catherine Wu, MD, at Dana-Farber.
“This is the first time it has been shown that a vaccine can generate immune cells against the tumor that can traffic from the bloodstream into a glioblastoma tumor,” said David Reardon, MD, senior author of the study. Reardon is clinical director of the Center for Neuro-Oncology at Dana-Farber.
Click here to read more.
5th International Conference on Spine and Spinal Disorders
April 25-26, 2019; Rome
2019 Annual MNNS Meeting
April 27, 2019; St. Paul, Minn.
GOODMAN Oral Board Preparation Course
May 1-3, 2019; Glendale, Ariz.
6th Annual Advanced Practice Provider Pediatric Neurosurgery Conference
May 2-3, 2019; Cincinnati
2019 Comprehensive Stroke Symposium
May 3-4, 2019; Rockville, Md.